01 Inflammation, Immunology and Immunotherapeutics Program

01炎症、免疫学和免疫治疗学(III)方案 摘要 几十年来对基础免疫学以及肿瘤和免疫系统的相互作用的研究导致了 在过去的几年里，免疫疗法在癌症方面的成功取得了爆炸性的增长。 炎症、免疫学和免疫疗法(III)计划的目标是在基础上和 通过开发新的治疗方法来加速这些成功 白血病/淋巴瘤和实体瘤，并了解和利用免疫系统的基本生物学 对癌症的反应。重点是抗体和T细胞介导的治疗在临床前模型和 临床翻译研究。肿瘤免疫学项目一直是癌症中心的一个组成部分 自成立以来和2012年，它与病毒学计划合并，成为III计划。它目前是 由Casey T.Weaver医学博士(病理学)和Donald J.Buchsbaum博士(放射肿瘤学)领导，并拥有 来自7个系的40名初级教职员工。该计划每年有11,611,410美元的直接赠款 对癌症相关研究的支持，包括来自NCI的756,267美元，来自其他NIH研究所的9,592,968美元， 289001美元来自其他同行审查的奖励，973 174美元来自非同行审查的支助。该计划有 两个主要的重点领域：(1)利用抗体特异性来开发靶向免疫疗法 向动物模型肿瘤和人类癌症传递凋亡刺激、药物或放射性同位素；以及(2) 探索炎症和T、B细胞免疫领域的基础免疫生物学研究 转化为免疫诊断和免疫治疗方式。该计划有重要的合作 与实验治疗学和癌细胞生物学计划，以及哈德逊阿尔法包括个人 乳腺癌和胰腺癌孢子的研究项目。在上一个资助期内，有 共有310份出版物，其中72份(23%)是方案内出版物，69份(22%)是方案间出版物，161份是方案内出版物 (52%)机构间。 1

01 INFLAMMATION, IMMUNOLOGY AND IMMUNOTHERAPEUTICS (III) PROGRAM ABSTRACT Decades of research on basic immunology and the interactions of tumors and the immune system have led over the past few years to an explosive increase in the successes of immunotherapeutic modalities in cancer. The objective of the Inflammation, Immunology, and Immunotherapeutics (III) Program is to build on and to accelerate those successes by developing novel therapeutic approaches for the treatment of leukemia/lymphoma and solid tumors, and to understand and exploit the basic biology of the immune system's responses to cancers. The emphasis is on antibody and T-cell mediated therapy in preclinical models and clinical translation studies. The Tumor Immunology Program has been a component of the Cancer Center since its inception and in 2012, it merged with the Virology Program to become the III Program. It is currently led by Casey T. Weaver, M.D. (Pathology), and Donald J. Buchsbaum, Ph.D. (Radiation Oncology), and has 40 primary faculty members from seven departments. The Program has $11,611,410 in annual direct grant support of cancer relevant research including $756,267 from NCI, $9,592,968 from other NIH Institutes, $289,001 from other peer-reviewed awards, and $973,174 in non-peer-reviewed support. The Program has two major areas of emphasis: (1) development of targeted immunotherapy utilizing antibody specificity to deliver apoptotic stimuli, drugs, or radioactive isotopes to tumors in animal models and human cancer; and (2) exploration of basic immunobiology research in the areas of inflammation and T- and B-cell immunology to translate into immunodiagnostic and immunotherapeutic modalities. The Program has major collaborations with the Experimental Therapeutics and Cancer Cell Biology Programs, and HudsonAlpha including individual projects in the Breast Cancer and Pancreatic Cancer SPOREs. During the previous funding period there were 310 total publications, of which 72 (23%) were intra-programmatic, 69 (22%) inter-programmatic, and 161 (52%) inter-institutional. 1